San Francisco, California, USA

Hims & Hers Health

American online health company. Its filings say it connects patients with licensed clinicians who can prescribe medicines when appropriate, with prescriptions filled by licensed pharmacies, across areas that include weight loss. It is not the maker of any approved GLP-1 drug. According to its filings, it began offering access to compounded injectable semaglutide in May 2024 and, in 2026, moved its US weight-loss offering towards branded GLP-1 medicines, with compounded versions offered on a limited scale. Compounded drugs are not FDA-approved. Figures and legal matters below are as the company reports them in its SEC filings.

2025 revenue

Hims & Hers reported total revenue of $2,347.6 million for 2025, up 59% from $1,476.5 million in 2024, and 2.511 million subscribers at the end of 2025.[src]

Second quarter 2026

In its quarterly report for the period ended 30 June 2026, Hims & Hers reported revenue of $753.2 million (up from $544.8 million a year earlier) and a net loss of $86.3 million. The report says the company evolved its US weight-loss offering to match its global approach of providing access to branded GLP-1 medications, and offering access to compounded GLP-1 medications on a limited scale.[src]

Eucalyptus acquisition

According to its quarterly report, in June 2026 Hims & Hers acquired Eucalyptus, a digital health and wellness platform headquartered in Australia (the company announced completion on 2 June 2026). The report gives an accounting purchase price of $968.5 million, including $225.0 million paid upfront, $683.9 million in deferred payments and contingent consideration valued at $59.6 million.[src]

Novo Nordisk patent lawsuit

According to Hims & Hers' quarterly report, Novo Nordisk sued the company on 9 February 2026 in the US District Court for the District of Delaware, alleging infringement of US Patent No. 8,129,343 in connection with compounded semaglutide products available through its platform. On 9 March 2026 Novo Nordisk voluntarily dismissed all claims without prejudice, and the report says it reserved the right to refile.[src]

Regulatory matters disclosed by the company

In its quarterly report Hims & Hers states that it received FDA warning letters in September 2025 about statements on its websites concerning compounded semaglutide, that in February 2026 HHS said in a statement on X that it had referred the company to the Department of Justice for investigation of potential violations of the Federal Food, Drug, and Cosmetic Act and applicable provisions of Title 18 of the US Code, and that in February 2026 the SEC Division of Enforcement notified it that it had opened an investigation concerning its public statements and disclosures about compounded semaglutide and related business relationships. The company says it is cooperating with the SEC investigation and cannot predict when or how it will be concluded. These are reported proceedings, not findings.[src]